OncoCyte Corp

OCX

NASDAQ. Currency in USD

0.48 -0.00 ( -0.02% )

Real time prices: December 06

Market Cap.
56.95M
Beta (5Y monthly)
1.64
Price/Earnings
-
EPS (TTM)
-0.38
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
90,885
1y Target Est.
1.80
Day's Range
0.47
-
0.49
52 Week's Range
0.36
-
2.68

Historical Summary

Performance
EPS growth
Share Buybacks

About OncoCyte Corp

Sector
Healthcare
Industry
Biotechnology
Website
https://oncocyte.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
92.23M
Employees
110
Address
15 Cushing, Irvine, CA, United States, 92618
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Latest news

Analyst Ratings for OncoCyte
Analyst Ratings for OncoCyte

OncoCyte (NASDAQ:OCX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish...
By Benzinga - 5 days ago

Expert Ratings for OncoCyte
Expert Ratings for OncoCyte

OncoCyte (NASDAQ:OCX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish...
By Benzinga - 5 days ago

Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022

Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy....
By Benzinga - 5 days ago

Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics...
By GlobeNewswire Inc. - 5 days ago

Oncocyte Announces Executive Leadership Changes
Oncocyte Announces Executive Leadership Changes

IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics...
By GlobeNewswire Inc. - 5 days ago

Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022

Upgrades According to Summit Insights Group, the prior rating for Applied Materials Inc (NASDAQ:AMAT) was...
By Benzinga - 2 weeks ago

OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?

OncoCyte (OCX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about...
By Zacks Investment Research - 2 weeks ago

Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday. Shares...
By Benzinga - 3 weeks ago